Integrated Filing — IndAS



General information about company

Scrip Code 538666
NSE Symbol SHARDACROP
MSEI Symbol NOTLISTED
ISIN INE221J01015
Name of company SHARDA CROPCHEM LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 13-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 05-05-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment The consolidated financial statements of the Company contains segment information as per IND AS 108 - Operating Segments accordingly separate information is not included in the Standalone financial results.
Start date and time of board meeting 13-05-2026   13:00:00
End date and time of board meeting 13-05-2026   14:30:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 24-01-2025
Indicate Company website link for updated RPT policy of the Company www.shardacropchem.com
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
Not Applicable



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 1,87,077.01 4,63,051.18
Other income 9,207.10 24,067.83
Total income 1,96,284.11 4,87,119.01
2 Expenses
(a) Cost of materials consumed 91,453.46 2,22,889.39
(b) Purchases of stock-in-trade (4,276.70) 79,329.94
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 30,496.58 (3,482.90)
(d) Employee benefit expense 2,015.93 5,623.75
(e) Finance costs 2.67 34.03
(f) Depreciation, depletion and amortisation expense 8,691.46 32,435.62
(f) Other Expenses
1 Foreign Exchange Gain/(Loss) 2,668.74 (2,983.69)
2 Other Expenses 20,262.54 68,844.13
Total other expenses 22,931.28 65,860.44
Total expenses 1,51,314.68 4,02,690.27
3 Total profit before exceptional items and tax 44,969.43 84,428.74
4 Exceptional items 0.00 0.00
5 Total profit before tax 44,969.43 84,428.74
6 Tax expense
7 Current tax 6,413.17 11,948.39
8 Deferred tax 3,315.87 4,748.46
9 Total tax expenses 9,729.04 16,696.85
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 35,240.39 67,731.89
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 35,240.39 67,731.89
17 Other comprehensive income net of taxes (5.03) (3.36)
18 Total Comprehensive Income for the period 35,235.36 67,728.53
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 9,022.05 9,022.05
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve 2,81,029.77
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 39.06 75.07
Diluted earnings (loss) per share from continuing operations 39.06 75.07
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 39.06 75.07
Diluted earnings (loss) per share from continuing and discontinued operations 39.06 75.07
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) Quarterly earnings per share is not annualised Notes 1. The aforesaid financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on May 13 2026. The statutory auditors have expressed an unmodified audit opinion on these results. 2. The financial results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Ind AS notified under the Companies Indian Accounting Standards Rules 2015 as amended from time to time. 3. The Board of Directors have recommended final dividend of Rs.9 per equity share of Rs.10 each fully paid up for the financial year 2025-2026 subject to the approval of shareholders at the ensuing Annual General Meeting. 4. The figures for the three months ended March 31 2026 and March 31 2025 are the balancing figures between the audited figures in respect of the full financial year ended on those dates and the published unaudited year to date figures upto December 31 2025 and December 31 2024 respectively. 5. Other expenses income includes loss gain on fair valuation of investments as under INR in Lakhs Particulars Three months ended Year ended March 31 December 31 March 31 March 31 March 31 2026 2025 2025 2026 2025 Loss or gain on fair valuation of 1450.25 182.25 287.35 1115.92 -805.37 investments 6. Other income includes INR in lakhs Particulars Three months ended Year ended March 31 December 31 March 31 March 31 March 31 2026 2025 2025 2026 2025 Dividend received from subsidiary 6889 4967.08 4327.62 13608.8 12374.21 7. One of the major segments of the Company viz. Agrochemicals is seasonal in nature and its performance can be impacted by cropping pattern and weather conditions across the globe. Accordingly quarterly figures are not representative of the other quarters and full year's performance. 8. The consolidated financial statements of the Company contains segment information as per IND AS 108 Operating Segments accordingly separate information is not included in the Standalone financial results.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 31-03-2026
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 225.21
Capital work-in-progress 0.00
Investment property 0.00
Goodwill 0.00
Other intangible assets 98,526.13
Intangible assets under development 24,723.63
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 653.72
Trade receivables, non-current 0.00
Loans, non-current 79.00
Other non-current financial assets
1 Other non-current financial assets 5,800.32
Total of other non-current financial assets 5,800.32
Total non-current financial assets 6,533.04
Deferred tax assets (net) 0.00
Other non-current assets
1 Income tax assets (net) 67.52
2 Other non- current assets 2,101.43
Total of other non-current assets 2,168.95
Total non-current assets 1,32,176.96
2 Current assets
Inventories 94,770.62
Current financial asset
Current investments 36,144.84
Trade receivables, current 2,23,365.60
Cash and cash equivalents 13,515.48
Bank balance other than cash and cash equivalents 7.46
Loans, current 1,684.07
Other current financial assets
Total of other current financial assets 12,379.01
Total current financial assets 2,87,096.46
Current tax assets (net) 0.00
Other current assets
1 Other current assets 19,856.46
Total of other current assets 19,856.46
Total current assets 4,01,723.54
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 5,33,900.50
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 9,022.05
Other equity 2,81,029.77
Total equity attributable to owners of parent 2,90,051.82
Non controlling interest
Total equity 2,90,051.82
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Other financial liabilities 3,544.20
Total of other non-current financial liabilities 3,544.20
Total non-current financial liabilities 3,544.20
Provisions, non-current 0.00
Deferred tax liabilities (net) 22,127.84
Deferred government grants, Non-current 0.00
Other non-current liabilities
Total of other non-current liabilities
Total non-current liabilities 25,672.04
Current liabilities
Current financial liabilities
Borrowings, current 0.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 766.98
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 1,40,028.39
Total Trade payable 1,40,795.37
Other current financial liabilities
1 Other current financial liabilities 64,066.71
Total of other current financial liabilities 64,066.71
Total current financial liabilities 2,04,862.08
Other current liabilities 4,706.28
1 Other current liabilities 4,706.28
Total of other current liabilities 4,706.28
Provisions, current 8,502.96
Current tax liabilities (Net) 105.32
Deferred government grants, Current 0.00
Total current liabilities 2,18,176.64
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 2,43,848.68
Total equity and liabilites 5,33,900.50
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-01-2026 01-04-2025
Date of end of reporting period 31-03-2026 31-03-2026
Whether results are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Gratuity (6.72) (4.49)
Total Amount of items that will not be reclassified to profit and loss (6.72) (4.49)
2 Income tax relating to items that will not be reclassified to profit or loss (1.69) (1.13)
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income (5.03) (3.36)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 31-03-2026
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 84,428.74
Adjustments for reconcile profit (loss)
Adjustments for finance costs 34.03
Adjustments for decrease (increase) in inventories (5,920.24)
Adjustments for decrease (increase) in trade receivables, current (37,925.67)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (11,841.85)
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current (5,827.38)
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 16,997.36
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 1,148.26
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 32,435.62
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 3,024.04
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains 3,782.46
Adjustments for dividend income 13,608.80
Adjustments for interest income 3,932.56
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) 1,115.92
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow (2,284.22)
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items (298.03)
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (23,101.06)
Net cash flows from (used in) operations 61,327.68
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 3,685.71
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 57,641.97
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 5.18
Purchase of property, plant and equipment 51.50
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 49,913.24
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 1,603.63
Cash receipts from repayment of advances and loans made to other parties 81.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 13,608.80
Interest received 2,417.90
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (3,926.46)
Net cash flows from (used in) investing activities (39,381.95)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 0.00
Repayments of borrowings 0.00
Payments of lease liabilities 775.97
Dividends paid 10,876.20
Interest paid 34.03
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (11,686.20)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 6,573.82
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 494.42
Net increase (decrease) in cash and cash equivalents 7,068.24
Cash and cash equivalents cash flow statement at beginning of period 6,447.24
Cash and cash equivalents cash flow statement at end of period 13,515.48





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 BSR & Co. LLP Yes 31-07-2028


Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Sharda Cropchem Limited Axis Crop Science Private Limited Wholly Owned Subsidiary Company Interest received 13.50 Nil 6.13 0.00 0.00
2 Sharda Cropchem Limited Axis Crop Science Private Limited Wholly Owned Subsidiary Company Any other transaction Loan Repaid 100.00 Nil 36.00 115.00 79.00
3 Sharda Cropchem Limited Axis Crop Science Private Limited Wholly Owned Subsidiary Company Any other transaction Rental Income 1.50 Nil 0.71 0.00 0.00
4 Sharda Cropchem Limited Sharda Do Brasil Comercio De Produtos Quimicos E Agroquimicos LTDA Wholly Owned Subsidiary Company Any other transaction Loan Given 15,000.00 Nil 942.95 668.99 1,684.07
5 Sharda Cropchem Limited Sharda Do Brasil Comercio De Produtos Quimicos E Agroquimicos LTDA Wholly Owned Subsidiary Company Interest received 15,000.00 Nil 21.28 0.00 21.28
6 Sharda Cropchem Limited Sharda Cropchem Espana S.L. Wholly Owned Subsidiary Company Sale of goods or services 60,000.00 Nil 35,376.38 7,433.53 23,415.87
7 Sharda Cropchem Limited Sharda Hungary Kft Wholly Owned Subsidiary Company Sale of goods or services 20,000.00 Nil 5,386.30 3,127.49 4,825.90
8 Sharda Cropchem Limited Sharda De Mexico S. De RL DE CV Step down Subsidiary Sale of goods or services 15,000.00 Nil 7,026.27 7,463.22 10,908.53
9 Sharda Cropchem Limited Sharda Poland SP.ZO.O Wholly Owned Subsidiary Company Sale of goods or services 1,20,000.00 Nil 66,101.80 18,139.48 42,822.87
10 Sharda Cropchem Limited Sharda International Africa (PTY) Ltd Step down Subsidiary Sale of goods or services 7,500.00 Nil 979.59 4,283.72 3,335.32
11 Sharda Cropchem Limited Sharda Colombia S.A.S Step down Subsidiary Sale of goods or services 2,400.00 Nil 587.57 1,053.63 1,117.03
12 Sharda Cropchem Limited Sharda Italia SRL Wholly Owned Subsidiary Company Sale of goods or services 25,000.00 Nil 16,943.01 9,295.55 16,314.20
13 Sharda Cropchem Limited Sharda Private (Thailand) Limited Wholly Owned Subsidiary Company Sale of goods or services 1,000.00 Nil 26.50 36.81 0.00
14 Sharda Cropchem Limited Sharda Do Brasil Comercio De Produtos Quimicos E Agroquimicos LTDA Wholly Owned Subsidiary Company Sale of goods or services 15,000.00 Nil 4,358.22 4,907.06 9,460.49
15 Sharda Cropchem Limited Sharda Maroc SARL Wholly Owned Subsidiary Company Sale of goods or services 2,000.00 Nil 185.62 492.46 278.93
16 Sharda Cropchem Limited Sharda International FZCO Wholly Owned Subsidiary Company Any other transaction Dividend Received 25,000.00 Nil 11,382.82 0.00 0.00
17 Sharda Cropchem Limited Sharda Cropchem Espana S.L. Wholly Owned Subsidiary Company Any other transaction Dividend Received 60,000.00 Nil 473.26 0.00 0.00
18 Sharda Cropchem Limited Shardaserb D.O.O. Wholly Owned Subsidiary Company Any other transaction Reimbursement of Expenses 100.00 Nil 29.32 0.00 3.98
19 Sharda Cropchem Limited Sharda Peru SAC Wholly Owned Subsidiary Company Any other transaction Reimbursement of Expenses 120.00 Nil 71.20 0.00 4.30
20 Sharda Cropchem Limited Sharda Del Ecuador Cia LTDA Wholly Owned Subsidiary Company Any other transaction Reimbursement of Expenses 150.00 Nil 52.12 0.00 10.27
21 Sharda Cropchem Limited Sharda Colombia S.A.S Step down Subsidiary Any other transaction Reimbursement of Expenses 100.00 Nil 28.89 8.44 1.41
22 Sharda Cropchem Limited Sharda Ukraine LLC Wholly Owned Subsidiary Company Any other transaction Reimbursement of Expenses 100.00 Nil 5.27 0.00 0.00
23 Sharda Cropchem Limited Sharda Do Brasil Comercio De Produtos Quimicos E Agroquimicos LTDA Wholly Owned Subsidiary Company Any other transaction Reimbursement of Expenses 15,000.00 Nil 285.03 0.00 295.34
24 Sharda Cropchem Limited Sharda Del Ecuador Cia LTDA Wholly Owned Subsidiary Company Any other transaction Reimbursement of Expenses 150.00 Nil 4.68 0.00 10.27
25 Sharda Cropchem Limited Sharda Peru SAC Wholly Owned Subsidiary Company Any other transaction Reimbursement of Expenses 120.00 Nil 6.94 0.00 0.00
26 Sharda Cropchem Limited Sharda Europe BVBA Step down Subsidiary Any other transaction Reimbursement of Expenses 100.00 Nil 3.20 0.00 0.00
27 Sharda Cropchem Limited Ramprakash Vilasrai Bubna Key Managerial Personnel Any other transaction Rent paid 270.00 Nil 135.00 0.00 0.00
28 Sharda Cropchem Limited Sharda Ramprakash Bubna Key Managerial Personnel Any other transaction Rent paid 270.00 Nil 135.00 0.00 0.00
29 Sharda Cropchem Limited Ashish Ramprakash Bubna Key Managerial Personnel Any other transaction Rent paid 86.40 Nil 43.20 0.00 0.00
30 Sharda Cropchem Limited Manish Ramprakash Bubna Key Managerial Personnel Any other transaction Rent paid 94.50 Nil 47.25 0.00 0.00
31 Sharda Cropchem Limited Seema Ashish Bubna Relative of Key Managerial Personnel Any other transaction Rent paid 44.55 Nil 22.28 0.00 0.00
32 Sharda Cropchem Limited Anisha Manish Bubna Relative of Key Managerial Personnel Any other transaction Rent paid 44.55 Nil 22.28 0.00 0.00
33 Sharda Cropchem Limited Ramprakash Vilasrai Bubna Key Managerial Personnel Remuneration Nil 125.32 0.00 0.00 Textual Information(1)
34 Sharda Cropchem Limited Sharda Ramprakash Bubna Key Managerial Personnel Remuneration Nil 18.75 0.00 0.00 Textual Information(2)
35 Sharda Cropchem Limited Ashish Ramprakash Bubna Key Managerial Personnel Remuneration Nil 96.30 0.00 0.00 Textual Information(3)
36 Sharda Cropchem Limited Manish Ramprakash Bubna Key Managerial Personnel Remuneration Nil 96.15 0.00 0.00 Textual Information(4)
37 Sharda Cropchem Limited Kevika Ashish Bubna Relative of Key Managerial Personnel Remuneration Nil 14.25 0.00 0.00 Textual Information(5)
38 Sharda Cropchem Limited Purav Manish Bubna Relative of Key Managerial Personnel Remuneration Nil 11.30 0.00 0.00 Textual Information(6)
39 Sharda Cropchem Limited Nitika Ashish Bubna Relative of Key Managerial Personnel Remuneration Nil 6.20 0.00 0.00 Textual Information(7)
40 Sharda Cropchem Limited Shailesh Anant Mehendale Key Managerial Personnel Remuneration Nil 52.82 0.00 0.00 Textual Information(8)
41 Sharda Cropchem Limited Jetkin Navinchandra Gudhka Key Managerial Personnel Remuneration Nil 13.56 0.00 0.00 Textual Information(9)
42 Axis Crop Science Private Limited Keval Furiya Key Managerial Personnel Remuneration Nil 1.46 0.00 0.00 Textual Information(10)
43 Axis Crop Science Private Limited Neha Gala Key Managerial Personnel Remuneration Nil 1.44 0.00 0.00 Textual Information(11)
44 Sharda Cropchem Limited Sonal Desai Independent Director Any other transaction Sitting fees Nil 3.60 0.00 0.00 Textual Information(12)
45 Sharda Cropchem Limited Shalin Divatia Independent Director Any other transaction Sitting fees Nil 2.70 0.00 0.00 Textual Information(13)
46 Sharda Cropchem Limited Vinod Kathuria Independent Director Any other transaction Sitting fees Nil 3.15 0.00 0.00 Textual Information(14)
47 Sharda Cropchem Limited Upendra Kamath Independent Director Any other transaction Sitting fees Nil 2.70 0.00 0.00 Textual Information(15)
48 Sharda Cropchem Limited Ramprakash Vilasrai Bubna Key Managerial Personnel Dividend paid Nil 843.16 0.00 0.00 Textual Information(16)
49 Sharda Cropchem Limited Sharda Ramprakash Bubna Key Managerial Personnel Dividend paid Nil 845.47 0.00 0.00 Textual Information(17)
50 Sharda Cropchem Limited Ashish Ramprakash Bubna Key Managerial Personnel Dividend paid Nil 910.80 0.00 0.00 Textual Information(18)
51 Sharda Cropchem Limited Manish Ramprakash Bubna Key Managerial Personnel Dividend paid Nil 910.80 0.00 0.00 Textual Information(19)
52 Sharda Cropchem Limited Seema Ashish Bubna Key Managerial Personnel Dividend paid Nil 270.00 0.00 0.00 Textual Information(20)
53 Sharda Cropchem Limited Anisha Manish Bubna Key Managerial Personnel Dividend paid Nil 270.00 0.00 0.00 Textual Information(21)
54 Sharda Cropchem Limited Shailesh Anant Mehendale Key Managerial Personnel Dividend paid Nil 0.01 0.00 0.00 Textual Information(22)
55 Sharda Cropchem Limited Jankidevi Bilasrai Bubna Trust Enterprised owned by Key Managerial Personnel Any other transaction Donation Paid Nil 8.50 0.00 0.00
Total value of transaction during the reporting period 1,55,234.51



Text Block

Textual Information(1) a. The value of the related party transactions is as per the appointment agreement signed between the Company and the KMP. Post employment benefits are actuarially determined on overall basis and hence not provided separately. b. Remuneration paid includes remuneration of Rs. 10.30 Lakhs received from Wholly Owned Subsidiaries.
Textual Information(2) The value of the related party transactions is as per the appointment agreement signed between the Company and the KMP. Post employment benefits are actuarially determined on overall basis and hence not provided separately.
Textual Information(3) The value of the related party transactions is as per the appointment agreement signed between the Company and the KMP. Post employment benefits are actuarially determined on overall basis and hence not provided separately.
Textual Information(4) The value of the related party transactions is as per the appointment agreement signed between the Company and the KMP. Post employment benefits are actuarially determined on overall basis and hence not provided separately.
Textual Information(5) The value of the related party transactions is as per the appointment agreement signed between the Company and the KMP. Post employment benefits are actuarially determined on overall basis and hence not provided separately.
Textual Information(6) The value of the related party transactions is as per the appointment agreement signed between the Company and the KMP. Post employment benefits are actuarially determined on overall basis and hence not provided separately.
Textual Information(7) The value of the related party transactions is as per the appointment agreement signed between the Company and the KMP. Post employment benefits are actuarially determined on overall basis and hence not provided separately.
Textual Information(8) The value of the related party transactions is as per the appointment agreement signed between the Company and the KMP. Post employment benefits are actuarially determined on overall basis and hence not provided separately.
Textual Information(9) The value of the related party transactions is as per the appointment agreement signed between the Company and the KMP. Post employment benefits are actuarially determined on overall basis and hence not provided separately.
Textual Information(10) The value of the related party transactions is as per the appointment agreement signed between the Company and the KMP. Post employment benefits are actuarially determined on overall basis and hence not provided separately.
Textual Information(11) The value of the related party transactions is as per the appointment agreement signed between the Company and the KMP. Post employment benefits are actuarially determined on overall basis and hence not provided separately.
Textual Information(12) The amount of sitting fees is as per approval by the Board of Directors of the Company.
Textual Information(13) The amount of sitting fees is as per approval by the Board of Directors of the Company.
Textual Information(14) The amount of sitting fees is as per approval by the Board of Directors of the Company.
Textual Information(15) The amount of sitting fees is as per approval by the Board of Directors of the Company.
Textual Information(16) The related party transactions do not require approval of Audit Committee, as it is offered to all the shareholders in proportion to their shareholding, uniformly.
Textual Information(17) The related party transactions do not require approval of Audit Committee, as it is offered to all the shareholders in proportion to their shareholding, uniformly.
Textual Information(18) The related party transactions do not require approval of Audit Committee, as it is offered to all the shareholders in proportion to their shareholding, uniformly.
Textual Information(19) The related party transactions do not require approval of Audit Committee, as it is offered to all the shareholders in proportion to their shareholding, uniformly.
Textual Information(20) The related party transactions do not require approval of Audit Committee, as it is offered to all the shareholders in proportion to their shareholding, uniformly.
Textual Information(21) The related party transactions do not require approval of Audit Committee, as it is offered to all the shareholders in proportion to their shareholding, uniformly.
Textual Information(22) The related party transactions do not require approval of Audit Committee, as it is offered to all the shareholders in proportion to their shareholding, uniformly.